Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

797 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Streptococcus toxic shock syndrome with severe pleuro-pulmonary necrosis].
Sato S, Abe S, Sekine S, Watanabe K, Saito J, Tsukada Y, Ishii T, Tanino Y, Ishida T, Munakata M. Sato S, et al. Among authors: tsukada y. Nihon Naika Gakkai Zasshi. 2008 Feb 10;97(2):420-2. doi: 10.2169/naika.97.420. Nihon Naika Gakkai Zasshi. 2008. PMID: 18323163 Japanese. No abstract available.
Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin.
Suzuki Y, Tanino Y, Nikaido T, Minemura H, Umeda T, Rikimaru M, Onuma T, Naito S, Takiguchi Y, Tomita H, Kawamata T, Togawa R, Sato Y, Uematsu M, Morimoto J, Kitakawa K, Tsukada Y, Nakamura K, Kanemitsu K, Iseki K, Shibata Y. Suzuki Y, et al. Among authors: tsukada y. Intern Med. 2021 Feb 1;60(3):457-461. doi: 10.2169/internalmedicine.6326-20. Epub 2020 Dec 15. Intern Med. 2021. PMID: 33328409 Free PMC article.
Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic.
Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kanbe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K. Suzuki Y, et al. Among authors: tsukada y. Int J Med Sci. 2022 May 9;19(5):834-841. doi: 10.7150/ijms.71132. eCollection 2022. Int J Med Sci. 2022. PMID: 35693744 Free PMC article.
Clinical effect of early administration of tocilizumab following the initiation of corticosteroid therapy for patients with COVID-19.
Kawamata T, Tanino Y, Nikaido T, Minemura H, Sato Y, Togawa R, Watanabe N, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Rikimaru M, Suzuki Y, Tsukada Y, Nakamura K, Kanemitsu K, Iseki K, Shibata Y. Kawamata T, et al. Among authors: tsukada y. J Infect Chemother. 2022 Dec;28(12):1639-1644. doi: 10.1016/j.jiac.2022.08.021. Epub 2022 Aug 31. J Infect Chemother. 2022. PMID: 36057415 Free PMC article.
Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic.
Suzuki Y, Shibata Y, Minemura H, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Iizuka T, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Waragai Y, Kambe T, Kanzaki N, Azuma T, Okamoto H, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Abe W, Tsukada Y, Lee T, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Hamaguchi S, Iseki K. Suzuki Y, et al. Among authors: tsukada y. Clin Exp Med. 2023 Oct;23(6):2715-2723. doi: 10.1007/s10238-022-00949-3. Epub 2022 Dec 5. Clin Exp Med. 2023. PMID: 36469171 Free PMC article.
Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19.
Shibata Y, Omae K, Minemura H, Suzuki Y, Nikaido T, Tanino Y, Fukuhara A, Kanno R, Saito H, Suzuki S, Ishii T, Inokoshi Y, Sando E, Sakuma H, Kobayashi T, Kume H, Kamimoto M, Aoki H, Takama A, Kamiyama T, Nakayama M, Saito K, Tanigawa K, Sato M, Kambe T, Kanzaki N, Azuma T, Sakamoto K, Nakamura Y, Ohtani H, Waragai M, Maeda S, Ishida T, Sugino K, Inage M, Hirama N, Furuyama K, Fukushima S, Saito H, Machiya JI, Machida H, Abe K, Iwabuchi K, Katagiri Y, Aida Y, Abe Y, Ota T, Ishizawa Y, Tsukada Y, Yamada R, Sato R, Onuma T, Tomita H, Saito M, Watanabe N, Rikimaru M, Kawamata T, Umeda T, Morimoto J, Togawa R, Sato Y, Saito J, Kanazawa K, Kurita N, Iseki K. Shibata Y, et al. Among authors: tsukada y. BMC Pulm Med. 2023 Aug 28;23(1):312. doi: 10.1186/s12890-023-02604-3. BMC Pulm Med. 2023. PMID: 37641057 Free PMC article.
Simple prediction tools for disease progression in unvaccinated patients with mild/moderate COVID-19 aged under 65 years: Simplified DOATS and DOAT scores.
Shibata Y, Minemura H, Suzuki Y, Nikaido T, Tanino Y, Rikimaru M, Kawamata T, Togawa R, Sato Y, Saito J, Kanazawa K, Iseki K; Doctors in Fukushima and Yamagata against COVID-19. Shibata Y, et al. Respir Investig. 2024 Jul;62(4):681-684. doi: 10.1016/j.resinv.2024.05.006. Epub 2024 May 22. Respir Investig. 2024. PMID: 38781788
797 results